Utama › Kanser Ovari › North Carolina › Durham
Kajian klinikal Kanser Ovari di Durham, NC
27 kajian untuk Kanser Ovari sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Mengambil pesertaSukarelawan sihat dialu-alukan
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Mengambil pesertaFasa 2/3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi jauh
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Duke University, Durham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Mengambil pesertaFasa 2
- University of North Carolina Medical Center /ID# 275307, Chapel Hill · 10 mi jauh
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Mengambil pesertaFasa 2
- Site 0259 - Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Mengambil pesertaKajian pemerhatian
- Research Site, Durham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Mengambil pesertaFasa 3
- Duke Cancer Institute, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Mengambil pesertaFasa 1
- Duke University Medical Center, Durham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Mengambil pesertaFasa 3
- Duke Cancer Center ( Site 0012), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- UNC- Chapel Hill, Chapel Hill · 10 mi jauh
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Mengambil pesertaFasa 3
- Duke, Durham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Mengambil peserta
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Mengambil pesertaFasa 1/2
- Duke University, Durham
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Mengambil pesertaFasa 3
- UNC Hospital, Chapel Hill · 10 mi jauh
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Mengambil pesertaFasa 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Mengambil pesertaFasa 3
- Duke Cancer Center, Durham
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Mengambil peserta
- Duke Cancer Center, Durham
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Mengambil pesertaFasa 1
- Site 0259, Durham
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Mengambil peserta
- Duke University Hospital, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Mengambil pesertaFasa 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Mengambil pesertaFasa 1
- Duke Cancer Institute, Durham
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Mengambil pesertaFasa 2
- Duke Cancer Center, Durham
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Mengambil peserta
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauh
Kajian Kanser Ovari di bandar lain
- Houston, TX89 kajian
- New York City, NY69 kajian
- Boston, MA61 kajian
- Los Angeles, CA50 kajian
- Nashville, TN49 kajian
- Arlington, VA46 kajian
- Philadelphia, PA44 kajian
- Columbus, OH39 kajian
- St. Louis, MO38 kajian
- Chicago, IL36 kajian
- San Antonio, TX31 kajian
- Cleveland, OH30 kajian
Kajian lain di Durham
- Kanser Payudara64 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Mieloma Pelbagai37 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Metastatik33 kajian
- Kanser Prostat32 kajian
- Kanser Paru-paru32 kajian
- Kanser Kolorektal28 kajian
- Leukemia Limfositik Kronik27 kajian
- Kegagalan Jantung26 kajian
- Kanser Pankreas24 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.